首页> 外文期刊>Molecular medicine. >Chemokine (C-X-C Motif) Receptor 4 and Atypical Chemokine Receptor 3 Regulate Vascular α1-Adrenergic Receptor Function
【24h】

Chemokine (C-X-C Motif) Receptor 4 and Atypical Chemokine Receptor 3 Regulate Vascular α1-Adrenergic Receptor Function

机译:趋化因子(C-X-C母体)受体4和非典型趋化因子受体3调节血管α1-肾上腺素受体的功能

获取原文
       

摘要

Chemokine (C-X-C motif) receptor (CXCR) 4 and atypical chemokine receptor (ACKR) 3 ligands have been reported to modulate cardiovascular function in various disease models. The underlying mechanisms, however, remain unknown. Thus, it was the aim of the present study to determine how pharmacological modulation of CXCR4 and ACKR3 regulate cardiovascular function. In vivo administration of TC14012, a CXCR4 antagonist and ACKR3 agonist, caused cardiovascular collapse in normal animals. During the cardiovascular stress response to hemorrhagic shock, ubiquitin, a CXCR4 agonist, stabilized blood pressure, whereas coactivation of CXCR4 and ACKR3 with CXC chemokine ligand 12 (CXCL12), or blockade of CXCR4 with AMD3100 showed opposite effects. While CXCR4 and ACKR3 ligands did not affect myocardial function, they selectively altered vascular reactivity upon α1-adrenergic receptor (AR) activation in pressure myography experiments. CXCR4 activation with ubiquitin enhanced α1-ARmediated vasoconstriction, whereas ACKR3 activation with various natural and synthetic ligands antagonized α1-AR-mediated vasoconstriction. The opposing effects of CXCR4 and ACKR3 activation by CXCL12 could be dissected pharmacologically. CXCR4 and ACKR3 ligands did not affect vasoconstriction upon activation of voltage-operated Ca2+ channels or endothelin receptors. Effects of CXCR4 and ACKR3 agonists on vascular α 1-AR responsiveness were independent of the endothelium. These findings suggest that CXCR4 and ACKR3 modulate α1-AR reactivity in vascular smooth muscle and regulate hemodynamics in normal and pathological conditions. Our observations point toward CXCR4 and ACKR3 as new pharmacological targets to control vasoreactivity and blood pressure
机译:据报道,趋化因子(C-X-C基序)受体(CXCR)4和非典型趋化因子受体(ACKR)3配体可在多种疾病模型中调节心血管功能。但是,其基本机制仍然未知。因此,本研究的目的是确定CXCR4和ACKR3的药理调节如何调节心血管功能。体内施用CXCR4拮抗剂和ACKR3激动剂TC14012在正常动物中引起心血管衰竭。在对出血性休克的心血管应激反应期间,泛素(一种CXCR4激动剂)可使血压稳定,而CXCR4和ACKR3与CXC趋化因子配体12(CXCL12)的共激活,或CXCR4与AMD3100的阻断显示出相反的作用。尽管CXCR4和ACKR3配体不影响心肌功能,但它们在压力肌成像实验中选择性地改变了α1-肾上腺素能受体(AR)激活后的血管反应性。 CXCR4激活与泛素增强了α1-AR介导的血管收缩,而ACKR3激活与各种天然和合成配体拮抗了α1-AR介导的血管收缩。 CXCL12激活CXCR4和ACKR3的相反作用可以通过药理学来分析。 CXCR4和ACKR3配体在电压操作的Ca2 +通道或内皮素受体激活后不影响血管收缩。 CXCR4和ACKR3激动剂对血管α1-AR反应性的影响独立于内皮细胞。这些发现表明,CXCR4和ACKR3在正常和病理情况下调节血管平滑肌中的α1-AR反应性并调节血液动力学。我们的观察指向CXCR4和ACKR3作为控制血管反应性和血压的新药理学靶标

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号